TLA Buster
Tired of TLAs (Three letter acronyms)? Try seaching on the acronym buster
Medical Abbreviations
Search By Abbreviation
Search By Definition
Medical Dictionary
Pharma Companies
Associations
www.medilexicon.com

Previous NSEP Event



Maximising growth through M&A


Monday 3rd July 2006, Four Seasons Hotel, London



Event timing

The event starts at 6.30pm (Registration from 6.00pm). The short talks and panel discussions last approximately 1 ¼ hours and will be followed by cocktails and canapés - the ideal networking opportunity.

About the event

Growth is back on the agenda. While the opportunity to grow through acquisition is greater than it has been in several years, in some ways, mergers and acquisitions are more challenging than ever. Shareholder expectations are higher, deals take longer to close and are very expensive.

Despite the obstacles to overcome, merger mania is expected to continue in the year ahead as big pharma corporations use more of their cash to buy biotechs, and biotech companies continue their consolidation spree. As well as being necessary for big pharma, there is also a knock-on effect on young biotech companies. For instance it is expected that we will see more M&A deals involving smaller Biotechs in the near future as VC's urge to get exits and bring a positive return to investors.

So companies now seemingly have choices: going public, merging, none of the above or all of the above. These choices are not mutually exclusive: public companies can (and do) merge with private and or other public companies. So what should smaller companies strive for? Can they sort out in advance which path to go down?

In particular, the following issues will be addressed:

  • Understanding the drivers behind M&A in the pharma/biotech industry
  • Extracting deal value - ensuring the integration is successful and synergies are captured on time
  • Making the acquired company part of your culture
  • What successful acquisitions have in common
  • Are contested acquisitions ever worth the aggro?
  • M&A versus other kinds of collaborations (JVs, licences etc.)
  • Building an in-house M&A capability
  • Is it possible to build a critical mass through M&A?
  • The current level of M&A financing - could more be done?
  • What kind of companies should consider an IPO and what sort should look to be acquired?
  • How to groom your company for a merger, sale or divestiture
  • What buyers are looking for now
  • How to identify and approach buyers


Networking evening

 One of the main reasons to attend this event is the opportunity to meet other key players within the industry, whether they be CEOs, Finance Directors, other key Directors, Consultants, Lawyers etc.

The cocktail party immediately following the event (it is almost worth coming for the famous Four Seasons canapés themselves!) is the ideal place to discuss matters in a less formal environment, whether this discussion is directly related to the event topic or not.
 

Who will attend?

Expected breakdown of job titles

 

Expected breakdown by audience sector







Outstanding speaker panel


Dr Nigel Parker PhD - Chief Executive Officer   Ark Therapeutics

Dr Nigel Parker, aged 52, has been Chief Executive Officer of Ark since 1997. He has built and steered the Group from one intellectual property filing of early stage pre-clinical science into its current stage of development, recruiting the key senior executive staff, executing two rounds of private equity funding totalling almost £30 million and the acquisition of Oy Quattrogene.

Since 1997 he has been responsible for the strategy and commercial focus of the Group. Throughout his career, he has played a key role in establishing and developing pharmaceutical and healthcare related companies. He was one of the founders of Walsh International Inc. (NASDAQ), a company that provided software and information services to the pharmaceutical industry, is a former European Vice President of Teva Pharmaceuticals Ltd and is a former European Vice President and corporate officer of Pharmaceutical Marketing Services Inc. (NASDAQ).



John Dawson - Chief Executive Officer   Alliance Pharmaceuticals Limited

John Dawson founded Alliance in 1996 he gained multi-disciplinary experience in the pharmaceutical industry over thirty years. John held various senior roles at Sandoz as director of finance and administration and deputy managing director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.



Michael Flynn - Chief Executive Officer   Sinclair Pharmaceuticals Limited

Dr. Flynn became Chief Executive Officer of Sinclair Pharma in August 2000 following a management buy-in of Sinclair Pharmaceuticals Limited, which he led. Between 1998 and 2000, Dr Flynn privately acquired the rights to a portfolio of products, which he brought to the Group. From June to November 1998, Dr. Flynn was acting Chief Executive Officer of Cortecs Group plc where he held the position of president between 1992 and June 1998 and of director between 1986 and 1992. Between 1976 and 1986, he was medical director and president of Technology International Limited, a Contract Research Organisation that Dr Flynn co-founded. Prior to 1976, Dr. Flynn had worked as senior medical advisor to Crookes Laboratories Limited, established Duphar Limited in the UK and spent approximately 5 years in the clinical research department of Philips Duphar in Holland. Dr. Flynn has spent over 30 years in the pharmaceutical industry and has served on the board of directors of approximately 30 private companies involved in the healthcare sector. Dr. Flynn was elected a fellow by Distinction of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians in 2001 and qualified as a physician from Kings College Hospital, London.



Viggo Birch - Managing Director   Novo Nordisk UK

Managing Director Novo Nordisk UK, Ireland, The Nordic Countries and Vice President Europe. Viggo is a Business Economist from Copenhagen Business School and Wharton School, Pennsylvania and has been 15 years with Novo Nordisk of which 11 years in Spain as Managing Director for Spain & Portugal. Started in the UK October 2001. Prior to Novo Nordisk worked 11 years with Mobil Oil in various sales, marketing and managerial positions. Latest as Director, Strategic Planning Benelux and the Nordic Countries based in Rotterdam from 1984 to 1987.

© NSEP 2007 - All rights reserved